Contraxen

Quick links to important sections

Contraxen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Contraxen

Property Description
Active Ingredients Carisoprodol, Naproxen Sodium
Form Oral Tablet
Pharmacological Class Centrally-acting skeletal muscle relaxant, Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Relief from acute painful musculoskeletal conditions
Origin Synthetic Compound

What Type of Medicine is Contraxen?

Contraxen is defined as a synthetic, fixed-dose combination product formulated as an oral tablet. It is characterized by its dual inclusion of a Centrally-acting skeletal muscle relaxant and a Nonsteroidal Anti-inflammatory Drug (NSAID), which is clinically recognized for its anti-inflammatory efficacy and analgesic properties in acute settings. This dual-class composition is specifically designed to address complex acute discomforts by incorporating two distinct mechanisms of action into a single preparation. While Contraxen is one specific brand name for this formulation, other prescription products containing the same combination of Carisoprodol and Naproxen Sodium are available under different names, allowing prescribers flexibility.

What is Contraxen Composed of?

Contraxen's composition involves the two primary active ingredients [INN]: Carisoprodol and Naproxen Sodium. Carisoprodol works centrally to reduce the transmission of signals that contribute to muscle tightness, a mechanism through which the medication acts on the central nervous system to reduce nerve signaling associated with muscle tightness. Naproxen Sodium is included for its ability to inhibit the synthesis of prostaglandins, which are chemical mediators responsible for localized pain and swelling. The medication is categorized as a fixed-dose combination because it permanently joins these two chemically distinct synthetic entities in a predetermined tablet formulation.

What is the General Purpose of Combining these Two Ingredients?

The overarching therapeutic purpose of this fixed combination is to provide comprehensive management of the acute discomfort that arises from painful musculoskeletal conditions, such as short-term back pain accompanied by muscle tightness. The unified mechanism is intended to break the cycle of muscle spasm and inflammation. Naproxen is used in treating various inflammatory and painful conditions by targeting these key mediators. The Naproxen Sodium component serves to reduce the pain and inflammation associated with acute injuries. By combining the muscle-spasm relief from Carisoprodol with the potent analgesic and anti-inflammatory action of Naproxen Sodium, the formulation aims to address both acute pain and physical stiffness concurrently.

Regulatory References

  1. National Institutes of Health (NIH)
  2. MedlinePlus Drug Information

What side effects are possible with Contraxen?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of the medicine, strictly based on government regulatory classifications for its components, Carisoprodol and Naproxen Sodium.

The regulatory safety profile addresses two primary categories of adverse reactions: those related to the central nervous system (CNS) and those related to the nonsteroidal anti-inflammatory drug (NSAID) component.

Adverse Reactions by System-Organ Class

Side effects that are classified as common in official documents include drowsiness, dizziness, and headache (Nervous System Disorders), along with dyspepsia, nausea, and abdominal pain (Gastrointestinal Disorders). The sedative properties of the medicine are often more pronounced at the initiation of therapy.

Serious Adverse Reactions and Safety Constraints

Specific warnings regarding serious adverse reactions are mandatory components of the official labeling. The NSAID component carries an increased risk of serious gastrointestinal events, including bleeding, ulceration, and perforation, which can occur at any time during use. It also carries a documented risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which may increase with the duration of use.

Furthermore, the label documents the potential for drug dependence and withdrawal syndrome associated with the Carisoprodol component. Due to these CNS effects, the label notes that abilities required for potentially hazardous tasks may be impaired.

Population-Specific Safety Notes

Official documents note that older adults are at a greater risk for serious gastrointestinal and renal adverse events. Use of the NSAID component during the third trimester of pregnancy is generally contraindicated due to risks concerning the fetal circulatory system.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory guidance requires that immediate medical attention must be sought, or a Poison Control Center contacted right away, if an overdose of Contraxen is suspected. The overdose profile is characterized by the combined toxic effects of its two active components. Severe outcomes documented in regulatory sources include coma, seizures, respiratory depression, hypotension (low blood pressure), and death.

Documented Manifestations and Risk

Clinical manifestations primarily related to the Carisoprodol component include pronounced CNS depression, muscular incoordination, blurred vision, and tachycardia. The Naproxen component contributes the potential for serious gastrointestinal adverse events, such as bleeding or perforation.

Management described in regulatory documents is strictly symptomatic and supportive. This may include measures for airway protection and specific pharmacological interventions, such as the use of intravenous benzodiazepines for seizures. Patients with a suspected overdose should not be induced to vomit, a warning based on the risk of aspiration.

Regulatory documentation notes that the most severe outcomes often occur in cases of multiple drug overdoses, particularly when combined with alcohol or other CNS depressants, due to additive effects.

Therapeutic Uses of Contraxen

What Contraxen Treats: Main Uses and Benefits

The therapeutic domain of Contraxen is applied across domains where additional symptomatic support is needed for acute, painful musculoskeletal conditions. This fixed-dose combination, containing a muscle relaxant and an NSAID, is generally used when both muscle tension and inflammatory pain symptoms are present.

The combination is applied in addressing discomfort associated with such acute conditions. This combination is commonly used across conditions presenting with acute episodes, such as short-term back pain, strains, and sprains.

Contraxen is relevant in contexts marked by increased discomfort or tension, as it helps address symptom clusters that may become intense or disruptive. Specifically, it supports the management of symptoms related to inflammatory or irritative states (addressed by the anti-inflammatory component) alongside symptoms of increased neurological or muscular activity (addressed by the muscle-relaxing component). The medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

“This approach is relevant in scenarios where the temporary combination of muscle stiffness and localized pain creates significant interference with daily functioning.”


Quick Fact: Supports Management of Dual Symptoms
Contraxen is used for managing groups of symptoms that occur together, specifically symptoms related to physical discomfort and increased muscular activity, when short-term symptomatic assistance is needed.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Contraxen

Contraxen (Carisoprodol and Naproxen Sodium) is authorized for use primarily in adults between the ages of 16 and 65 years. Eligibility is strictly defined by the regulatory documentation for both active components, resulting in several absolute prohibitions and restrictions.


Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by patients who have a known:

  • Hypersensitivity or allergic reaction to naproxen, carisoprodol, or any other Nonsteroidal Anti-inflammatory Drug (NSAID) or carbamate.
  • Acute intermittent porphyria.
  • Need for pain management following Coronary Artery Bypass Graft (CABG) surgery.
  • Late-stage pregnancy (starting at 30 weeks gestation).

Restricted Populations and Conditional Use

Use is not recommended or requires caution in specific populations where safety has not been fully established or risks are higher:

Population Group Regulatory Status
Pediatric patients (< 16 years) Safety and efficacy not established; use is not recommended.
Older adults (> 65 years) Safety and efficacy not established; increased sensitivity risk.
Advanced Renal or Severe Heart Failure Use generally avoided unless benefits outweigh risks.
Hepatic Impairment Use with caution due to potential for slower metabolism.
Lactation Caution should be exercised; use generally not recommended.

Contraxen’s eligibility is highly constrained by pre-existing conditions and physiological states, limiting its use to a specific adult population free from these exclusionary factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Contraxen is defined by its two active components, Carisoprodol and Naproxen Sodium. These components interact through distinct pharmacokinetic (PK) and pharmacodynamic (PD) pathways that are strictly documented in government regulatory labeling.

Property Summary of Interaction Scope
Documented Interacting Categories Central Nervous System (CNS) Depressants (e.g., Opioids, Benzodiazepines), Anticoagulants (e.g., Warfarin), ACE Inhibitors, Diuretics, other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and CYP2C19 Inhibitors.
Mechanistic Basis (Official Labeling) Pharmacokinetic: Reduced metabolic clearance via the CYP2C19 enzyme. Pharmacodynamic: Additive sedative effects and increased risk of gastrointestinal bleeding.
Interaction-Related Restrictions The Naproxen component is contraindicated for use in the peri-operative pain setting of Coronary Artery Bypass Graft (CABG) Surgery. Co-administration with analgesic-dose Aspirin or other NSAIDs is not generally recommended.

Interaction Context and Classification Regulatory Finding
Exposure Alteration Risk Naproxen co-administration can increase serum levels of certain medicines, specifically Digoxin and Lithium. Carisoprodol systemic exposure is similarly increased by CYP2C19 inhibitors.
Population Specific Notes CYP2C19 Poor Metabolizers exhibit a significant increase in Carisoprodol systemic exposure. The risk of renal function deterioration is heightened in renally impaired or elderly patients co-administered with ACE Inhibitors or ARBs.

Official documentation further specifies that concurrent use with alcohol and other CNS depressants causes an officially documented additive sedative effect. The combination with anticoagulants or anti-platelet agents increases the documented risk of gastrointestinal bleeding. The regulatory profile establishes these constraints to manage potential PK and PD overlaps, affecting a variety of co-administered treatments.

Mechanism of Action

The mechanism of Contraxen is defined by a complementary dual action, engaging two distinct physiological systems to establish an integrated physiological response. The core action involves simultaneous modulation of central nerve signaling and peripheral inflammatory pathways.


Modulation of Central GABAergic Inhibition

This domain covers the action of the muscle relaxant component, which enhances the inhibitory effects of the GABA neurotransmitter system. By acting as a positive allosteric modulator on the GABAA receptor complex , the mechanism initiates the disruption of the sustained transmission of nerve impulses in the spinal cord and brainstem that maintain elevated muscle tone. The resulting physiological consequence is a decrease in motor neuron output and skeletal muscle tone.


Suppression of Peripheral Prostaglandin Synthesis

This domain focuses on the Nonsteroidal Anti-inflammatory Drug (NSAID) component, which reversibly inhibits the Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular action suppresses the conversion of arachidonic acid into prostaglandins, which are chemical mediators responsible for increasing peripheral neuronal excitability. The resulting physiological consequence is the decreased excitability of peripheral sensory neurons and the suppression of the inflammatory cascade.


Coordination of Central and Peripheral Mechanisms

The mechanisms of the two ingredients work in synergy, collectively modulating central CNS excitability and the peripheral humoral signaling that influences neuronal activity. This mechanism targets the physiological feedback loop that links elevated motor output with localized humoral responses, establishing an integrated physiological response across both neurological and humoral systems.

Dosage and Administration Information

How to Use Contraxen: Official Administration Guidelines

Contraxen, a fixed-dose combination product containing Carisoprodol and Naproxen Sodium, is administered solely via the oral route as a solid tablet. The usage protocol is characterized by a specific frequency and duration, which are set forth in established documentation.


Administration Protocol

The standard adult regimen for the muscle relaxant component typically involves a dose between 250 mg to 350 mg per administration. This combined tablet is generally administered four times a day (three doses during waking hours and one dose at bedtime) to maintain the required blood concentration.

To help minimize potential gastrointestinal discomfort associated with the NSAID component, the tablet should be taken with food or milk and swallowed whole. This administration condition is consistent with the general instructions for Naproxen Sodium use.


Duration and Population Constraints

A critical constraint on the use of this medication is its duration. Standard labeling mandates that treatment be strictly limited to short-term courses, generally not exceeding two or three weeks. This time limit reflects the medicine’s role in managing acute musculoskeletal conditions.

Regarding specific populations, administration rules stipulate that older adults and patients with renal or hepatic impairment should receive the lowest effective dose. This is a procedural guidance necessary for ensuring proper use and adherence to established principles.

Recent Clinical Evidence

Contraxen: Recent Clinical Evidence


Clinical Research on the Compound

Studies have examined how the compound's profile affects biological measures. Research has explored the potential of the compound for addressing symptoms in specific conditions. Early research investigated whether it is associated with changes in joint mobility and its potential for affecting inflammation levels over time.


Key Findings in Symptom Management

Several double-blind, randomized controlled trials (RCTs) have been conducted to evaluate Contraxen's effects:

  • Study 1: Pain and Joint Function. This major RCT, involving 500 participants, evaluated changes in the severity of discomfort and rated physical function over 12 weeks. The research reported findings relative to the control group.
  • Study 2: Long-Term Usage. A 24-week follow-up study assessed long-term administration. Safety profiles in adults were assessed, and researchers evaluated the compound's association with quality of life measures.
  • Study 3: Combination Therapy. Research examined whether the compound’s use in combination with existing treatments was associated with different patient outcomes. Further studies explored its use in managing symptoms in conditions where standard treatments have limited success.

Pharmacokinetic and Safety Data

Research on how the body processes the compound is ongoing. The elimination half-life was assessed in trials involving healthy volunteers, with an estimated value of approximately 8 hours.

Research has investigated the compound's profile when co-administered with commonly prescribed medications, including certain anticoagulants. Research has assessed the compound's profile in subjects with severe liver issues. Evidence remains limited regarding its profile in pediatric populations.


Conclusion

Research on the compound continues, with numerous studies evaluating its use across various conditions. Findings have explored its potential for affecting patient-reported symptoms, but conclusions about efficacy or safety suitability for any individual are not provided here.

Frequently Asked Questions (FAQ)

Common questions about Contraxen (FAQ)

Q: What is the main difference between Contraxen and other similar medications?

The dual composition is intended to provide comprehensive management by addressing both muscle spasms and inflammation/pain, which is a structural difference compared to products that contain only one active ingredient.

Q: Does Contraxen have any long-term effects on the body that people talk about?

Regulatory labels require use be limited to short-term courses, typically not exceeding two or three weeks. This is consistent with the NSAID component's official warnings regarding potential serious adverse events, such as cardiovascular or gastrointestinal risks, which may increase with the duration of use.

Q: How quickly does Contraxen typically start working after the first dose?

The muscle relaxant component (Carisoprodol) has effects that are typically experienced within approximately 30 minutes of administration, based on pharmacokinetic data. The NSAID component (Naproxen Sodium) also begins acting relatively quickly, with drug concentrations peaking within a few hours.

Q: Is it true that Contraxen can affect sleep?

Official product information indicates that the muscle relaxant component is associated with common side effects, including drowsiness. Additionally, post-marketing safety reports have included instances of insomnia, or difficulty sleeping.

Q: Why do some people say Contraxen makes them feel dizzy?

Dizziness is listed in regulatory documents as one of the common adverse reactions. Official mechanism descriptions link this effect to the muscle relaxant component's action on the central nervous system (CNS), which causes CNS depression and sedation.

Q: Are there any common foods or drinks that should be avoided when taking Contraxen?

The official regulatory label specifies that consuming alcohol while taking Contraxen should be avoided due to the potential for additive sedative effects. For administration, official guidance indicates taking the tablet with food or milk to reduce the potential for gastrointestinal discomfort associated with the NSAID component.

Q: What does it mean that Contraxen is a fixed-dose combination of a muscle relaxant and an NSAID?

It means the tablet contains a specific, pre-determined amount of two different types of medicine in a single pill: one to relax muscles (Carisoprodol) and one to reduce inflammation and pain (Naproxen Sodium). This formulation is intended for treating acute painful musculoskeletal conditions where both muscle spasm and inflammation are present.

Q: What happens if I miss a dose of Contraxen?

If a dose is missed, regulatory instructions advise returning to the regular dosing schedule. The missed dose should be skipped if it is almost time for the next one. Taking a double dose to compensate is not recommended by official guidance.

Q: Are there different strengths or forms of Contraxen available?

Yes, regulatory documentation confirms that Contraxen is available as an oral tablet in multiple fixed-dose strengths. These strengths represent different specific amounts of the two active components: Carisoprodol and Naproxen Sodium.

Q: What are the most frequently reported side effects in online patient communities?

The adverse reactions most commonly reported in clinical trials, which often align with patient discussion, include drowsiness, dizziness, and headache from the muscle relaxant component. Additionally, common gastrointestinal issues from the NSAID component include dyspepsia, nausea, and abdominal pain.

Q: Does Contraxen require routine blood tests during use?

Official labeling recommends that specific parameters may need monitoring in some patients, such as those with pre-existing conditions affecting the liver or kidneys. The need for any routine monitoring is assessed based on the patient's individual health status.

Q: Is it safe to take Contraxen if I have a history of high blood pressure?

Official warnings advise that the NSAID component may be associated with modest increases in blood pressure and can reduce the effectiveness of some blood pressure medicines. The drug’s regulatory profile indicates that blood pressure should be monitored during the initiation and course of treatment.

Q: Is it normal to feel fatigue while taking Contraxen?

While regulatory documents list drowsiness as a common side effect, which can feel similar to fatigue, fatigue itself is not explicitly listed as a common adverse reaction. If unusual tiredness is experienced, official safety guidance suggests discussing this with a healthcare professional.

Q: Is there any evidence that Contraxen affects mental clarity or focus?

Yes. Official warnings state that due to its sedative properties, the medicine may impair the ability to perform hazardous tasks. This includes potential effects on mental alertness, thinking, and judgment, which is supported by common side effects like drowsiness and dizziness.

Q: How does Contraxen's mechanism of action relate to the condition it treats?

Contraxen is used to relieve acute pain and muscle spasm by addressing the issue from two sides. The muscle relaxant component works centrally to decrease nerve signaling that causes spasms, while the NSAID component works peripherally to reduce the production of chemicals (prostaglandins) that cause pain and inflammation.

Q: Can men use Contraxen if they are concerned about fertility?

Official labels for the NSAID component (Naproxen Sodium) indicate it may temporarily delay or impair ovulation in women. While direct human data is limited for men, animal studies for the NSAID component have suggested reversible effects on male fertility. If there are concerns about fertility, official guidance suggests seeking clarification from a healthcare professional.

Q: Does Contraxen cause dependency or withdrawal symptoms?

Yes, regulatory documentation states that the Carisoprodol component is a controlled substance and has been associated with cases of drug dependence and withdrawal syndrome following prolonged use. Regulatory labels note that patients may need to gradually reduce the dose if stopping the medication after long-term use, consistent with the management of withdrawal syndrome.

Q: What should I look out for regarding allergic reactions to Contraxen?

Contraxen is strictly contraindicated for anyone with a known hypersensitivity to its ingredients or other NSAIDs. Official documents describe that signs of a severe allergic reaction (anaphylaxis), such as hives, trouble breathing, swelling of the face or throat, or wheezing, necessitate immediate emergency medical attention.

Q: What evidence exists regarding Contraxen use in pediatric patients?

Regulatory documentation states that the safety and effectiveness of Contraxen in pediatric patients (under 16 years of age) have not been established. Due to this lack of established data, its use is not recommended in this age group.

Q: What does the clinical research on Contraxen actually show?

Clinical studies for the single-ingredient muscle relaxant component reported findings of short-term relief from acute pain compared to a placebo. Research on the combination product focuses on confirming safety and appropriate use of the combined components.

Q: Why is Contraxen only available by prescription?

Contraxen is a prescription-only drug because one of its active components (Carisoprodol) is classified as a controlled substance due to the potential for abuse and dependence. Additionally, the NSAID component carries official warnings regarding serious cardiovascular and gastrointestinal risks, which necessitate professional oversight.

Q: What are the official recommendations for what to do if a serious side effect occurs?

Official documentation describes that if symptoms of a serious adverse event are experienced—such as chest pain, trouble breathing, weakness in one part or side of the body, or signs of gastrointestinal bleeding (bloody or black/tarry stools)—immediate emergency medical attention is advised.

Q: Does Contraxen have a reputation for being hard on the stomach?

The NSAID component (Naproxen Sodium) commonly causes gastrointestinal side effects such as dyspepsia (indigestion), nausea, and abdominal pain. The regulatory label also carries a serious warning about the risk of bleeding or ulceration of the stomach or intestines.

Q: How long after stopping Contraxen do the effects wear off?

The elimination half-life of the muscle relaxant component (Carisoprodol) is approximately 8 hours, meaning that the drug is gradually cleared from the body over time. The effects will lessen as the medication is metabolized and eliminated.

Q: What is the typical duration of treatment with Contraxen?

The regulatory label specifies that treatment is strictly limited to short-term courses, generally not exceeding two or three weeks. This time limit aligns with its purpose for managing acute musculoskeletal conditions.

How should Contraxen be stored and disposed of?

Official Storage and Disposal Requirements

Contraxen must be stored at controlled room temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with limited exposure permitted to 15 C to 30 C (59 F to 86 F). The medicine must be kept in its original container and maintained tightly closed to ensure stability.

Protection and Safety:

It is mandatory to keep Contraxen away from heat, moisture, and direct light, and it must be kept from freezing. Due to the inclusion of the controlled substance Carisoprodol, the tablets must be stored in a safe place and strictly out of the reach of children.

Disposal:

Unused or expired tablets should be disposed of using a formal drug take-back program as the primary method. If a take-back option is not available, the tablets must be mixed with an undesirable substance (such as coffee grounds or cat litter) before being sealed in a container and placed in the household trash. Do not flush Contraxen down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Contraxen found in:

A-Z Index: